138 related articles for article (PubMed ID: 9081136)
1. Efficacy of a new prostaglandin E1 regimen in outpatients with severe intermittent claudication: results of a multicenter placebo-controlled double-blind trial.
Diehm C; Balzer K; Bisler H; Bulling B; Camci M; Creutzig A; Gruss JD; Horsch S; Odemar F; Piehler U; Rogatti W; Scheffler P; Spengel F; Treese N; Turowski A; Waldhausen P; Weber B; Weiss T
J Vasc Surg; 1997 Mar; 25(3):537-44. PubMed ID: 9081136
[TBL] [Abstract][Full Text] [Related]
2. Impact of a 4-week treatment with prostaglandin E1 on health-related quality of life of patients with intermittent claudication.
Mangiafico RA; Messina R; Attinà T; Dell'Arte S; Giuliano L; Malatino LS
Angiology; 2000 Jun; 51(6):441-9. PubMed ID: 10870853
[TBL] [Abstract][Full Text] [Related]
3. Treatment of severe intermittent claudication with PGE1--a short-term vs a long-term infusion plan--a 20 week, European randomized trial--analysis of efficacy and costs.
Belcaro G; Laurora G; Nicolaides AN; Agus G; Cesarone MR; DeSanctis MT; Incandela L; Ricci A; Cazaubon M; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Iacobitti P; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Bucci M; Ferrari PG; Corsi M; Pomante P; Mezzanotte L; Geroulakos G
Angiology; 1998 Nov; 49(11):885-94; discussion 895. PubMed ID: 9822044
[TBL] [Abstract][Full Text] [Related]
4. PGE(1) treatment of severe intermittent claudication (short-term versus long-term, associated with exercise)--efficacy and costs in a 20-week, randomized trial.
Belcaro G; Nicolaides AN; Agus G; Cesarone MR; Geroulakos G; Pellegrini L; De Sanctis MT; Incandela L; Ricci A; Mondani P; De Angelis R; Ippolito E; Barsotti A; Vasdekis S; Ledda A; Christopoulos D; Errichi BM; Helmis H; Cornelli U; Ramaswami G; Dugall M; Bucci M; Martines G; Ferrari PG; Corsi M; Di Francescantonio D
Angiology; 2000 Aug; 51(8 Pt 2):S15-26. PubMed ID: 10959507
[TBL] [Abstract][Full Text] [Related]
5. [European trial of PGE1 alpha cyclodextrin. Short-term vs. long-term therapy in intermittent claudication].
Laurora G; Corsi M; Bucci M; Cesarone MR; Belcaro G; Dugall M
Minerva Cardioangiol; 1998 Oct; 46(10 Suppl 1):21-9. PubMed ID: 10658441
[TBL] [Abstract][Full Text] [Related]
6. Randomized, double-blind, placebo-controlled study evaluating the efficacy and safety of AS-013, a prostaglandin E1 prodrug, in patients with intermittent claudication.
Belch JJ; Bell PR; Creissen D; Dormandy JA; Kester RC; McCollum RD; Mizushima Y; Ruckley CV; Scurr JH; Wolfe JH
Circulation; 1997 May; 95(9):2298-302. PubMed ID: 9142008
[TBL] [Abstract][Full Text] [Related]
7. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
Böger RH; Bode-Böger SM; Thiele W; Creutzig A; Alexander K; Frölich JC
J Am Coll Cardiol; 1998 Nov; 32(5):1336-44. PubMed ID: 9809945
[TBL] [Abstract][Full Text] [Related]
8. [Treatment of severe intermittent claudication: ORACLE-PGE1 short term study. A randomised 40-week study. Evaluation of efficacy and costs].
Cesarone MR; Belcaro G; Nicolaides AN; Griffin M; Geroulakos G; Ramaswami G; Cazaubon M; Barsotti A; Vasdekis S; Christopoulos D; Agus G; Bavera P; Mondani P; Ippolito E; Flenda F
Minerva Cardioangiol; 2002 Dec; 50(6):683-90. PubMed ID: 12473989
[TBL] [Abstract][Full Text] [Related]
9. Progress in the prostaglandin E1-therapy of the intermittent claudication by means of bolus injections of LIPO-prostaglandin E1 (LIPO-PGE1).
Scheffler P; Gross J; Markwirth T; Maier J; Schieffer H
Eur J Clin Pharmacol; 1996; 51(3-4):235-9. PubMed ID: 9010691
[TBL] [Abstract][Full Text] [Related]
10. Effects of a 4-week treatment with prostaglandin E1 on plasma endothelin-1 release in patients with intermittent claudication.
Mangiafico RA; Malatino LS; Santonocito M; Messina R; Attinà T; Dell'Arte S; Sarnataro F
Int J Clin Pharmacol Ther; 1999 Jul; 37(7):347-51. PubMed ID: 10442509
[TBL] [Abstract][Full Text] [Related]
11. Effects of regular physical training in a supervised class and additional intravenous prostaglandin E1 and naftidrofuryl infusion therapy in patients with intermittent claudication--a controlled study.
Diehm C; Kühn A; Strauss R; Hübsch-Müller C; Kübler W
Vasa Suppl; 1989; 28():26-30. PubMed ID: 2609241
[TBL] [Abstract][Full Text] [Related]
12. A new pharmacological treatment for intermittent claudication: results of a randomized, multicenter trial.
Beebe HG; Dawson DL; Cutler BS; Herd JA; Strandness DE; Bortey EB; Forbes WP
Arch Intern Med; 1999 Sep; 159(17):2041-50. PubMed ID: 10510990
[TBL] [Abstract][Full Text] [Related]
13. Prostaglandin E1 -containing nanoparticles improve walking activity in an experimental rat model of intermittent claudication.
Ishihara T; Yamashita Y; Takasaki N; Yamamoto S; Hayashi E; Tahara K; Takenaga M; Yamakawa N; Ishihara T; Kasahara T; Mizushima T
J Pharm Pharmacol; 2013 Aug; 65(8):1187-94. PubMed ID: 23837586
[TBL] [Abstract][Full Text] [Related]
14. Oral Beraprost sodium, a prostaglandin I(2) analogue, for intermittent claudication: a double-blind, randomized, multicenter controlled trial. Beraprost et Claudication Intermittente (BERCI) Research Group.
Lièvre M; Morand S; Besse B; Fiessinger JN; Boissel JP
Circulation; 2000 Jul; 102(4):426-31. PubMed ID: 10908215
[TBL] [Abstract][Full Text] [Related]
15. Improvement of peripheral and cardiopulmonary performance after a short-term exercise program with additive prostaglandin E1.
Cachovan M; Rogatti W
Angiology; 2001 Jun; 52(6):381-91. PubMed ID: 11437028
[TBL] [Abstract][Full Text] [Related]
16. Liposomal prostaglandin E1 (TLC C-53) in acute respiratory distress syndrome: a controlled, randomized, double-blind, multicenter clinical trial. TLC C-53 ARDS Study Group.
Abraham E; Baughman R; Fletcher E; Heard S; Lamberti J; Levy H; Nelson L; Rumbak M; Steingrub J; Taylor J; Park YC; Hynds JM; Freitag J
Crit Care Med; 1999 Aug; 27(8):1478-85. PubMed ID: 10470753
[TBL] [Abstract][Full Text] [Related]
17. [Rehabilitation program in patients with moderate-to-severe intermittent claudication: immediate results and one year follow-up].
Rossini D; Bulckaen M; Di Marco S; Giovannetti R; Giuntoli F; Lacopetti L; Vergoni W
Monaldi Arch Chest Dis; 2007 Jun; 68(2):110-4. PubMed ID: 17886772
[TBL] [Abstract][Full Text] [Related]
18. [Severe intermittent claudication: PGE1 treatment. A 40-week registry, efficacy and costs].
Luzzi R; Belcaro G; Ippolito E; Dugall M; Cesarone MR; Scoccianti M; Errichi BM; Pellegrini L; Ciammaichella G; Ledda A; Ricci A; Cornelli U; Feragalli B; Hosoi M; Corsi M; Simeone E; Agus GB
Minerva Cardioangiol; 2012 Aug; 60(4):405-13. PubMed ID: 22858918
[TBL] [Abstract][Full Text] [Related]
19. Effect of cilostazol on walking distances in patients with intermittent claudication caused by peripheral vascular disease.
Money SR; Herd JA; Isaacsohn JL; Davidson M; Cutler B; Heckman J; Forbes WP
J Vasc Surg; 1998 Feb; 27(2):267-74; discussion 274-5. PubMed ID: 9510281
[TBL] [Abstract][Full Text] [Related]
20. Demonstration of the efficacy of ginkgo biloba special extract EGb 761 on intermittent claudication--a placebo-controlled, double-blind multicenter trial.
Peters H; Kieser M; Hölscher U
Vasa; 1998 May; 27(2):106-10. PubMed ID: 9612115
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
